Bristol-Myers Extends License for Genome Therapeutics Database | GenomeWeb
Home » Bristol-Myers Extends License for Genome Therapeutics Database

Bristol-Myers Extends License for Genome Therapeutics Database

Dec 06, 2000

NEW YORK, Dec 6 - Genome Therapeutics said Wednesday that Bristol-Myers Squibb had renewed its license for the PathoGenome database, extending a subscription that began in 1997.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Articles

Jun 07, 2016

Bristol-Myers Squibb, MD Anderson Ink Immuno-Oncology Research Deal

Feb 23, 2016

ImmunID, Memorial Sloan Kettering to Validate Cancer Immunotherapy Companion Dx

May 12, 2016

HTG Molecular Diagnostics Q1 Revenues Dip 14 Percent

Oct 09, 2015

Agilent's Dako Lands FDA Approval for Lung Cancer Complementary Dx

Jan 11, 2016

SomaLogic Inks Deal With BMS for Use of SOMAscan Platform

Apr 19, 2016

AstraZeneca Study Finds High Concordance in Comparison of Three PD-L1 Assays

Premium

The Scan

This Week in Nature

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Some Cold Water

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA-Based Wanted Sketch

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

So, What's This Exactly?

Researchers discuss the need for antibody standards at a meeting, NPR reports.

Sponsorships

Privacy Policy.  Copyright © 2016 Genomeweb LLC.  All Rights Reserved.